首页> 外国专利> A SMALL MOLECULE INHIBITOR OF MYD88 FOR THERAPEUTIC TREATMENT AGAINST ALPHAVIRUS AND STAPHYLOCOCCAL ENTEROTOXIN INFECTIONS AND TOXIN EXPOSURE

A SMALL MOLECULE INHIBITOR OF MYD88 FOR THERAPEUTIC TREATMENT AGAINST ALPHAVIRUS AND STAPHYLOCOCCAL ENTEROTOXIN INFECTIONS AND TOXIN EXPOSURE

机译:MYD88的一种小分子抑制剂,用于治疗阿尔法病毒和葡萄球菌肠毒素感染和毒素暴露

摘要

A synthetic molecule 4210 and a therapeutic use of a synthetic small molecule 4210 for treating viral infections, especially encephalitic alphavirus infections. The compound 4210 showed antiviral efficacy by up regulation type 1 interferon (IFN) specifically IFN-β. The compound 4210 was designed and synthesized by a structure-based approach targeting intracellular adaptor protein, myeloid differentiation primary response protein 88 (MyD88). Besides having an antiviral effect, the compound 4210 also demonstrated therapeutic efficacy for treating inflammatory syndrome associated with Gram positive bacterial infections such as exposure to staphylococcal enterotoxin B (SEB) induced toxic shock syndrome (TSS) in mice and can potentially be used in clinical set up for treating sepsis and septic shock. In addition, the application of molecule 4210 can treat sepsis and septic shock triggered by exposure to other biological agents such as Francisella tularensis or Burkholderia mallei known to cause tularemia and glanders, respectively. The molecule 4210 has the potential for a broad-spectrum therapeutic use.
机译:合成分子4210和合成小分子4210在治疗病毒感染,特别是脑性α病毒感染中的治疗用途。化合物4210通过上调1型干扰素(IFN)特别是IFN-β表现出抗病毒功效。化合物4210通过针对细胞内衔接蛋白,髓样分化一级反应蛋白88(MyD88)的基于结构的方法进行设计和合成。除具有抗病毒作用外,化合物4210还显示出治疗与革兰氏阳性细菌感染相关的炎症综合症的治疗功效,例如暴露于小鼠的葡萄球菌肠毒素B(SEB)诱导的中毒性休克综合症(TSS),可潜在地用于临床用于治疗败血症和败血性休克。此外,分子4210的应用可以治疗败血症和败血症性休克,这些脓毒症和败血症性休克是由于暴露于其他生物制剂(例如分别引起图拉米氏菌和腺体的图拉弗朗西斯菌或马氏伯克霍尔德氏菌)引起的。分子4210具有潜在的广谱治疗用途。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号